source
- CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancerCG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…
- Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conferenceBiopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…